Mouse Genome Informatics
cn
    Tg(Kit*D814V)3Roer/0
Tg(Mx1-cre)1Cgn/0

involves: C57BL/6 * CBA
Key:
phenotype observed in females WTSI Wellcome Trust Sanger Institute
phenotype observed in males EuPh Europhenome
N normal phenotype
       
mortality/aging
• 1 pIpC treated mouse was euthanized due to severe disease at 12 weeks of age

digestive/alimentary system
• in mice with intestinal inflammation
• in mice with intestinal inflammation
• diarrhea with bloody feces is seen in mice with intestinal inflammation
• in a few mice, regardless of pIpC treatment
• rare

hematopoietic system
• most of the mast cells in pIpC treated mice with mastocytosis are round with some degree of hypergranulation and only few spindle shaped cells are seen
• mice treated with 3 injections of pIpC every second day at 4 to 10 weeks of age develop diffuse mastocytosis by 13 - 38 weeks of age
• pIpC treated mice display a variable increase in cutaneous mast cell numbers
• in some pIpC treated mice accumulations of mast cells are seen in the lymph nodes
• mice not treated with pIpC develop phenotypes similar to those in pIpC injected mice
• in mice with leukemia
• bone marrow cells are unable to engraft in nonirradiated recipient mice

tumorigenesis
• some pIpC treated mice develop large numbers of dermal mast cell tumors of variable size
• in a few mice these tumors are macroscopically visible
• mice not treated with pIpC develop phenotypes similar to those in pIpC injected mice
• some mice, regardless of pIpC treatment, develop a condition resembling B-lymphoblastic leukemia

growth/size
• in mice with intestinal inflammation

integument
• some pIpC treated mice develop large numbers of dermal mast cell tumors of variable size
• in a few mice these tumors are macroscopically visible
• mice not treated with pIpC develop phenotypes similar to those in pIpC injected mice

immune system
• in a few mice, regardless of pIpC treatment
• rare
• most of the mast cells in pIpC treated mice with mastocytosis are round with some degree of hypergranulation and only few spindle shaped cells are seen
• mice treated with 3 injections of pIpC every second day at 4 to 10 weeks of age develop diffuse mastocytosis by 13 - 38 weeks of age
• pIpC treated mice display a variable increase in cutaneous mast cell numbers
• in some pIpC treated mice accumulations of mast cells are seen in the lymph nodes
• mice not treated with pIpC develop phenotypes similar to those in pIpC injected mice
• in mice with leukemia

Mouse Models of Human Disease
OMIM IDRef(s)
Mast Cell Disease 154800 J:169611